At the same time, the fusion of CRISPR-dCas9 and epigenetic editing tools (such as dCas9-METTL3 fusion protein) can achieve site-specific RNA methylation editing, providing a new paradigm for the treatment of genetic diseases [210]. This evidence concerns the gene METTL3 and hereditary disease.